CTLA4 and melanoma: The emergence of immunotherapy, including PD-1 inhibitors (e.g., nivolumab and pembrolizumab) and anti-CTLA-4 agents (e.g., ipilimumab), has marked a paradigm shift in the management of stage III melanoma [1,11].